Loading...
•
Dec 31, 2025
Veracyte Q4 2025 Earnings Report
Veracyte Q4 2025 Earnings Report: The company delivered strong double-digit growth in its core testing business and achieved record profitability.
Key Takeaways
Veracyte concluded 2025 with a strong fourth quarter, growing total revenue by 19% to $140.6 million. The growth was primarily driven by the Decipher and Afirma tests, which saw revenue increases of 27% and 16% respectively. The company achieved a significant GAAP net income of $41.1 million and generated over $50 million in cash from operations during the quarter.
Total revenue grew 19% year-over-year to $140.6 million, with testing revenue up 21%.
Decipher revenue increased 27% to $85.6 million, while Afirma revenue grew 16% to $47.9 million.
GAAP net income reached $41.1 million, representing 29.3% of revenue, a 705% improvement over the prior year.
Adjusted EBITDA margin expanded to 30.1%, reflecting best-in-class profitability alongside strong growth.
Revenue by Segment
Forward Guidance
Veracyte reiterated its 2026 revenue guidance and provided adjusted EBITDA margin expectations.
Positive Outlook
- Reiterated 2026 total revenue growth of 10% to 13%.
- Testing revenue growth expected to be 14% to 16%.
- Expected adjusted EBITDA margin of approximately 25%.
- Planned launch of Prosigna as an LDT.
- Upcoming launch of TrueMRD to expand reach in cancer care.
Challenges Ahead
- Biopharmaceutical and other revenue impacted by Veracyte SAS liquidation.
- Guidance excludes potential contributions from new tests.
- Inherent difficulty in forecasting GAAP measures for forward-looking periods.
- Potential impact of foreign currency fluctuations.
- Ongoing regional conflicts and global banking turmoil risks.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...